Since CTLA-4 mAbs has been approved for immunotherapy of melanoma and is in clinical trial for combination with PD-1 mAbs (49–51) our data suggest combination of IL36 with CTLA-4 mAbs might be of clinical significance to further increase its efficacy. Here, CTLA4 is linked to melanoma.